Castrate-resistant Prostate Cancer Market Trends

Purvaja Jadhao

posted on 10 months ago — updated on 2 seconds ago

70
views

The global Castrate-resistant Prostate Cancer Market is estimated to be valued at US$ 9.5 Bn in 2022 and is expected to exhibit a CAGR of 8.2% over the forecast period 2021 to 2028, as highlighted in a new report published by Coherent Market Insights

Castrate-resistant Prostate Cancer Market Trends

Market Overview:
Prostate cancer is a prevalent form of cancer affecting men's prostate gland. Castrate-resistant prostate cancer (CRPC) is an advanced form in which cancer still grows despite reducing testosterone levels. Treatment for CRPC includes chemotherapy, hormone therapy, immunotherapy, radiotherapy which reduces risk of painful symptoms.

Market key trends:
One of the key market trends is the approvals of new generation drugs. The FDA and EMA bodies have approved several new treatment options like Abiraterone acetate and Enzalutamide which have significantly improved survival rates in CRPC patients. These novel drugs provide alternatives to conventional docetaxel chemotherapy and represent a paradigm shift in treatment. They have witnessed strong uptake post approval and are major revenue generators for companies. This has propelled market growth of CRPC over past decade.

Segment Analysis
The Castrate-resistant Prostate Cancer (CRPC) market can be segmented by drug class into chemotherapy, hormonal therapy, immunotherapy, and radiation therapy. Hormonal therapy accounts for the largest market share as it is the most preferred line of treatment after chemotherapy fails. Hormonal therapy drugs Zytiga and Xtandi dominate this segment as they result in median survival rates above 18 months.

Key Takeaways
The global Castrate-Resistant Prostate Cancer Market is expected to witness high growth, exhibiting a CAGR of 8.2% over the forecast period from 2023 to 2030, due to increasing prevalence of prostate cancer across the world.

Market size
The global Castrate-resistant Prostate Cancer market size is expected to reach US$ 9.5 Bn in 2021 and is projected to reach over US$ 18.7 Bn by 2030. This growth is attributed to the rising geriatric population globally which is more prone to develop prostate cancer.

Regional analysis
North America dominates the global CRPC market led by increasing research funding from both private and public sources in the US. Europe holds the second largest market share led by countries like Germany, France and the UK. The Asia Pacific region is expected to be the fastest growing market led by improving healthcare infrastructure and increasing awareness about prostate cancer in countries like China and India.

Key players
Key players operating in the Castrate-resistant Prostate Cancer market are Sanofi, Johnson & Johnson Services Inc., Pfizer Inc., Astellas Pharma Inc., Bayer AG, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis International AG, Eli Lilly & Company, and AstraZeneca plc. Sanofi and Johnson & Johnson Services Inc. are the market leaders due to their wide portfolio of CRPC drugs like Zytiga and Erleada respectively.